DexCom, Inc.
NASDAQDXCM delivered a Q2 earnings beat that flipped the script entirely — the defensive hedging that dominated the pre-print note has given way to a broad analyst upgrade cycle and the stock's strongest weekly move in months. The price action tells the story first. DXCM closed Friday at $83.45, up nearly 12% on the day after the July 30 print and 16.6% on the week. That contrasts…
Snapshot as of 14 Aug 2026
DXCM delivered a Q2 earnings beat that flipped the script entirely — the defensive hedging that dominated the pre-print note has given way to a broad analyst upgrade cycle and the stock's strongest weekly move in…
DXCM heads into tonight's Q2 earnings report with options traders flashing their most defensive positioning in nearly a year. The put/call ratio has climbed to 1.00, more than two standard deviations above its 20-day…
DexCom enters the week after a 29% one-month rally with an unusual split: analysts are lifting targets in its wake, yet options traders just registered their most defensive positioning of the year — a tension worth…
DexCom heads into its Q1 2026 earnings report with options markets flashing their most cautious signal in months. The put/call ratio jumped to 1.05 on the day of the print — nearly three standard deviations above its…
Options traders are pricing in more pain for DXCM. Three bearish signals converged this week — rising short interest, a spiking put-call ratio, and a higher cost to borrow — all arriving just 12 days before DexCom's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DXCM — free to start on ORTEX.
Sign up for free →Open DXCM on ORTEX